Mo'tasem M Alsmadi (Motasem M Alsmadi, Mo'tasem Alsmadi, Motasem Alsmadi)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 21

Top Topics

Irritable Bowel Syndrome

Oxide Nanoparticles

Low Birth Weight

Top Venues

AAPS PharmSciTech

Drug development and industrial pharmacy

Biopharmaceutics & drug disposition

Therapeutic drug monitoring

This page only lists publications with an associated author ORCID identifier.

Publications

Hadeia Mashaqbeh, Rana M Obaidat, Mo'tasem M Alsmadi
Solvent-Free Method for Masking the Bitter Taste of Azithromycin Dihydrate Using Supercritical Fluid Technology. Drug development and industrial pharmacy (2024)
Dyala M Khasawneh, Rami J Oweis, Mo'tasem M Alsmadi
A Comprehensive Analysis of Liposomal-Based Nanocarriers for Treating Skin and Soft Tissue Infection. Current drug delivery (2024)
Mo'tasem M Alsmadi
Salivary Therapeutic Monitoring of Buprenorphine in Neonates After Maternal Sublingual Dosing Guided by Physiologically Based Pharmacokinetic Modeling. Therapeutic drug monitoring (2024)
Mo'tasem M Alsmadi
Salivary Therapeutic Monitoring of Buprenorphine in Neonates After Maternal Sublingual Dosing Guided by Physiologically Based Pharmacokinetic Modeling. Therapeutic drug monitoring 46 (4) (2024)
Hadeia Mashaqbeh, Rana M Obaidat, Mo'tasem M Alsmadi
Solvent-free method for masking the bitter taste of azithromycin dihydrate using supercritical fluid technology. Drug development and industrial pharmacy 50 (2) (2024)
Mo'tasem M Alsmadi, Alla A Abudaqqa, Nasir Idkaidek, Nidal A Qinna, Ahmad Al-Ghazawi
The Effect of Inflammatory Bowel Disease and Irritable Bowel Syndrome on Pravastatin Oral Bioavailability: In vivo and in silico evaluation using bottom-up wbPBPK modeling. AAPS PharmSciTech 25 (4) (2024)
Hadeia Mashaqbeh, Rana M Obaidat, Mo'tasem M Alsmadi
Solvent-free method for masking the bitter taste of azithromycin dihydrate using supercritical fluid technology. Drug development and industrial pharmacy 50 (2) (2024)
Mo'tasem M Alsmadi, Alla A Abudaqqa, Nasir Idkaidek, Nidal A Qinna, Ahmad Al-Ghazawi
The Effect of Inflammatory Bowel Disease and Irritable Bowel Syndrome on Pravastatin Oral Bioavailability: In vivo and in silico evaluation using bottom-up wbPBPK modeling. AAPS PharmSciTech 25 (4) (2024)
Hadeia Mashaqbeh, Rana M Obaidat, Mo'tasem M Alsmadi
Solvent-free method for masking the bitter taste of azithromycin dihydrate using supercritical fluid technology. Drug development and industrial pharmacy (2024)
Mo'tasem M Alsmadi, Alla A Abudaqqa, Nasir Idkaidek, Nidal A Qinna, Ahmad Al-Ghazawi
The Effect of Inflammatory Bowel Disease and Irritable Bowel Syndrome on Pravastatin Oral Bioavailability: In vivo and in silico evaluation using bottom-up wbPBPK modeling. AAPS PharmSciTech 25 (4) (2024)
Mo'tasem M Alsmadi
Evaluating the Pharmacokinetics of Fentanyl in the Brain Extracellular Fluid, Saliva, Urine, and Plasma of Newborns from Transplacental Exposure from Parturient Mothers Dosed with Epidural Fentanyl Utilizing PBPK Modeling. European journal of drug metabolism and pharmacokinetics (2023)
Mo'tasem M Alsmadi, Nasir Idkaidek
The Analysis of Pethidine Pharmacokinetics in Newborn Saliva, Plasma, and Brain Extracellular Fluid After Prenatal Intrauterine Exposure from Pregnant Mothers Receiving Intramuscular Dose Using PBPK Modeling. European journal of drug metabolism and pharmacokinetics (2023)
Mo'tasem M Alsmadi, Mays M Jaradat, Rana M Obaidat, Mohammad Alnaief, Rabab Tayyem, Nasir Idkaidek
The In Vitro, In Vivo, and PBPK Evaluation of a Novel Lung-Targeted Cardiac-Safe Hydroxychloroquine Inhalation Aerogel. AAPS PharmSciTech 24 (6) (2023)
Mo'tasem M Alsmadi, Nour M Al-Daoud, Rana M Obaidat, Niazy A Abu-Farsakh
Enhancing Atorvastatin In Vivo Oral Bioavailability in the Presence of Inflammatory Bowel Disease and Irritable Bowel Syndrome Using Supercritical Fluid Technology Guided by wbPBPK Modeling in Rat and Human. AAPS PharmSciTech 23 (5) (2022)
Mo'tasem M Alsmadi, Nusaiba K Al-Nemrawi, Rana Obaidat, Anwar E Abu Alkahsi, Khetam M Korshed, Ishraq K Lahlouh
Insights into the mapping of green synthesis conditions for ZnO nanoparticles and their toxicokinetics. Nanomedicine (London, England) 17 (18) (2022)
Mo'tasem M Alsmadi
The investigation of the complex population-drug-drug interaction between ritonavir-boosted lopinavir and chloroquine or ivermectin using physiologically-based pharmacokinetic modeling. Drug metabolism and personalized therapy (2022)
Mo'tasem M Alsmadi, Saja B Alzughoul
In vitro-in vivo extrapolation of bexarotene metabolism in the presence of chronic kidney disease and acute kidney injury in rat using physiologically based pharmacokinetic modeling and extrapolation to human. Biopharmaceutics & drug disposition (2022)
Mo'tasem M Alsmadi, Nour M Al-Daoud, Mays M Jaradat, Saja B Alzughoul, Amani D Abu Kwiak, Salam S Abu Laila, Ayat J Abu Shameh, Mohammad K Alhazabreh, Sana'a A Jaber, Hala T Abu Kassab
Physiologically-based pharmacokinetic model for alectinib, ruxolitinib, and panobinostat in the presence of cancer, renal impairment, and hepatic impairment. Biopharmaceutics & drug disposition 42 (6) (2021)
Mo'tasem M Alsmadi, Rana M Obaidat, Mohammad Alnaief, Borhan Aldeen Albiss, Nabil Hailat
Development, In Vitro Characterization, and In Vivo Toxicity Evaluation of Chitosan-Alginate Nanoporous Carriers Loaded with Cisplatin for Lung Cancer Treatment. AAPS PharmSciTech 21 (5) (2020)
Nasir M Idkaidek, Salim Hamadi, Rabab Bani-Domi, Ibrahim Al-Adham, Mo'tasem M Alsmadi, Faten Awaysheh, Hisham Aqrabawi, Ahmad Al-Ghazawi, Ayman Rabayah
Saliva versus Plasma Therapeutic Drug Monitoring of Gentamicin in Jordanian Preterm Infants. Development of a Physiologically-Based Pharmacokinetic (PBPK) Model and Validation of Class II Drugs of Salivary Excretion Classification System. Drug research 70 (10) (2020)
Mo'tasem M Alsmadi, Mahdi Qasem Alfarah, Jawaher Albderat, Ghazi Alsalaita, Reham AlMardini, Salim Hamadi, Ahmad Al-Ghazawi, Omar Abu-Duhair, Nasir M Idkaidek
The development of a population physiologically based pharmacokinetic model for mycophenolic mofetil and mycophenolic acid in humans using data from plasma, saliva, and kidney tissue. Biopharmaceutics & drug disposition 40 (9) (2019)